Nausea: Clinical Trials

15 trials for Nausea, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

15 terminated. 15 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 215Terminated 15
Phase 11Terminated 1
Phase 31Terminated 1

Follow Nausea: new trials by email Literature Review of Nausea trials Research Report on Nausea

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
BHV-3500 (zavegepant), Placebo - Migraine
Phase 2 / Phase 3TerminatedPfizer17532021-03-262025-03-27
Validating the Effect og Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum
Mirtazapine, Ondansetron, Placebo - Hyperemesis Gravidarum, Nausea Gravidarum
Phase 2TerminatedNordsjaellands Hospital582019-03-012023-01-30
Efficacy of Extended-release, Once Daily Tramadol for Post Operative Analgesia in Shoulder Arthroscopy
tramadol, Placebo - Pain, Vertigo
Phase 2TerminatedCentre hospitalier de l'Université de Montréal (CHUM)1002013-06-012020-07-24
Dexamethasone for the Treatment of Established Postoperative Nausea and Vomiting
Placebo, Dexamethasone 3 mg, Dexamethasone 6 mg - Postoperative Nausea and Vomiting, Vomiting
Phase 2TerminatedUniversity Hospital, Geneva2562012-09-032019-12-10
Fosaprepitant (MK-0517, EMEND® IV) In Salvage Treatment of Chemotherapy-Induced Vomiting (MK-0517-030)
Fosaprepitant dimeglumine, 5-HT3 RA, Dexamethasone - Nausea, Vomiting
Phase 2TerminatedMerck Sharp & Dohme LLC1112011-10-252018-08-27
Aprepitant and Granisetron for the Prophylaxis of Radiation Induced Nausea and Vomiting - A Pilot Study
Aprepitant, Palliative radiation therapy, Granisetron - Nausea, Vomiting
Phase 2TerminatedSunnybrook Health Sciences Centre192011-01-012019-10-09
Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients
Palonosetron - Nausea, Vomiting
Phase 2TerminatedUniversity of Michigan Rogel Cancer Center32010-11-012015-12-04
Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents
Oral Aprepitant, Aprepitant - Nausea, Vomiting
Phase 2TerminatedThe Hospital for Sick Children42010-10-012017-04-19
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
palonosetron hydrochloride, placebo - Anal Cancer, Carcinoma of the Appendix
Phase 2TerminatedAlliance for Clinical Trials in Oncology72009-09-012017-11-24
Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy
fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride - Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx
Phase 2TerminatedUniversity of Washington62009-02-012017-05-18
Fosaprepitant Dimeglumine in Treating Patients With Nausea and Vomiting Caused By Chemotherapy
fosaprepitant dimeglumine, systemic chemotherapy, survey administration - Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
Phase 1 / Phase 2TerminatedOHSU Knight Cancer Institute342008-08-012017-05-09
Study of Nicotine for the Prevention of PONV
Nicotine - Postoperative Nausea and Vomiting
Phase 2TerminatedUniversity Hospital, Geneva2002007-10-012009-09-29
Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy
Decadron®, Benadryl®, Ativan® - Nausea, Vomiting
Phase 2TerminatedUniversity of South Florida72007-10-012014-07-25
Comparison of Delta-8-THC to Ondansetron in the Prevention of Acute Nausea From Moderately Emetogenic Chemotherapy
inhaled delta-8-THC 300mcg or 600mcg per dose - Cancer
Phase 2TerminatedRafa Laboratories62005-11-012020-12-23
12 Weeks Treatment With DDP225 or Placebo in Patients With Chronic Functional Vomiting
DDP225 - Vomiting
Phase 2TerminatedDynogen Pharmaceuticals302005-11-012007-10-12

Narrower conditions

Vomiting (12)  ·  Postoperative Nausea and Vomiting (2)  ·  Anus Neoplasms (1)  ·  Appendiceal Neoplasms (1)  ·  Bile Duct Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Colonic Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Gallbladder Neoplasms (1)  ·  Hyperacusis (1)  ·  Hyperemesis Gravidarum (1)  ·  Liver Neoplasms (1)  ·  Migraine Disorders (1)  ·  Neoplasms (1)

Broader conditions

Pathological Conditions, Signs and Symptoms (15)  ·  Signs and Symptoms (15)  ·  Signs and Symptoms, Digestive (15)  ·  Carcinoma (2)  ·  Ear Diseases (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms by Site (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Nervous System Diseases (2)  ·  Neurologic Manifestations (2)  ·  Otorhinolaryngologic Diseases (2)  ·  Pathologic Processes (2)  ·  Postoperative Complications (2)  ·  Adenocarcinoma (1)

Interventions

Dexamethasone (4)  ·  Aprepitant (3)  ·  Ondansetron (3)  ·  Palonosetron (3)  ·  fosaprepitant (3)  ·  Calcium Dobesilate (2)  ·  Adrenal Cortex Hormones (1)  ·  Cisplatin (1)  ·  Diphenhydramine (1)  ·  Granisetron (1)  ·  Lorazepam (1)  ·  Mirtazapine (1)  ·  Neoadjuvant Therapy (1)  ·  Nicotine (1)  ·  Radiotherapy (1)

Sponsors

University Hospital, Geneva (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Centre hospitalier de l'Université de Montréal (CHUM) (1)  ·  Dynogen Pharmaceuticals (1)  ·  Merck Sharp & Dohme LLC (1)  ·  Nordsjaellands Hospital (1)  ·  OHSU Knight Cancer Institute (1)  ·  Pfizer (1)  ·  Rafa Laboratories (1)  ·  Sunnybrook Health Sciences Centre (1)  ·  The Hospital for Sick Children (1)  ·  University of Michigan Rogel Cancer Center (1)  ·  University of South Florida (1)  ·  University of Washington (1)

Countries

United States (7)  ·  Canada (3)  ·  Switzerland (2)  ·  Denmark (1)  ·  Israel (1)  ·  Puerto Rico (1)

Top investigators

Anne Ostenfeld, MD (1)  ·  Christoph Czarnetzki, MD (1)  ·  Daniel Bertrand, PhD (1)  ·  Edward Chow, MBBS PhD FRCPC (1)  ·  Haydar Frangoul, MD (1)  ·  Jean-Denis Roy, Doctor (1)  ·  Joseph Bubalo, PharmD, BCPS, BCOP (1)  ·  Keith Eaton (1)  ·  Lee Dupuis, RPh, MScPhm, ACPR, FCSH (1)  ·  Michele Yvette Halyard, MD (1)  ·  Nathan Cherny, MD (1)

Results publications

PMID 32209630, PMID 34799501, PMID 41478546, PMID 42645743

NIH funding

P30CA069533 (1), U10CA081920 (1)